Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMIO1K0)

Drug Name
Sulfamylon Drug Info
Synonyms
Mafenide; mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Maphenide; Maphenid; Malfamin; Homosul; Homonal; Benzamsulfonamide; Homosulfanilamide; Marprontil; Mesudrin; Septicid; Neofamid; Mesudin; Paramenyl; 4-Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Homosulfaminum; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; 4-sulfamoylbenzylamine; Bensulfamide; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(aminosulfonyl)benzylamine; Mafenide acetate; MAFENIDE
Cross-matching ID
PubChem CID
3998
ChEBI ID
CHEMBL419
CAS Number
CAS 138-39-6
TTD Drug ID
D0K1QD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.06 7.13e-3 34/36 (94.44%) RPA3;RFC3;MCM2;...
Proximal tubule bicarbonate reclamation 2.00 7.13e-3 21/23 (91.3%) SLC4A4;ATP1A1;CA2;...
Cell cycle 1.98 7.13e-3 110/124 (88.71%) CDC25B;CHEK1;MCM2;...
Prostate cancer -1.71 4.63e-2 93/97 (95.88%) KLK3;SPINT1;BAD;...
Cytokine-cytokine receptor interaction -1.74 3.78e-2 246/295 (83.39%) CCL16;IL17A;BMPR1B;...
Longevity regulating pathway -1.74 4.06e-2 90/151 (59.6%) HSPA1A;ULK1;CREB1;...
SNARE interactions in vesicular transport -1.77 3.75e-2 19/33 (57.58%) STX16;BNIP1;STX11;...
Other glycan degradation -1.79 2.98e-2 13/18 (72.22%) MAN2C1;HEXB;AGA;...
Rheumatoid arthritis -1.82 2.39e-2 78/93 (83.87%) TEK;ATP6V1D;TNFRSF11A;...
Malaria -1.84 2.09e-2 44/50 (88%) CD36;TNF;CD81;...
NF-kappa B signaling pathway -1.86 2.28e-2 90/104 (86.54%) CSNK2A2;ZAP70;TNFSF11;...
Viral protein interaction with cytokine and cytokine re... -1.86 3.05e-2 84/100 (84%) IL10RA;CCL5;CCR7;...
TNF signaling pathway -1.89 3.92e-2 103/112 (91.96%) IL15;FOS;MMP9;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H